Fig. 4

Histological fluorescence analysis of TXNIP, cleaved Caspase-3 (CC3) and BCL-2 expression after TXNIP siRNA and RES treatment. TXNIP was co-localized with TUNEL-positive cells in the hippocampus and subcortex (n = 3, IX71, Olympus, Japan); TXNIP (red), TUNEL (green), DAPI (nucleus, blue); original magnification: subcortex, ×200; hippocampus, ×400. Scale bars: 120 μm (a) and 60 μm (b). Representative Western blot of CC3 and BCL-2 (c, f). Densitometric quantification of protein band optical densities for CC3 and BCL-2 (d, e, g, h). RES and siRNA injection significantly inhibited CC3 expression and increased the generation of BCL-2. Results were analysed using the Fusion system (fx 7 Spectra, Vilber, France). Results are expressed as a percentage of the values for β-actin. Quantitative TUNEL-positive cells count after siRNA and RES treatment; original magnification ×400 (i, j, n = 5, Olympus microscopy, Japan). Scale bars: i 60 μm. ^# p < 0.05 vs. sham, *p < 0.05 vs SAH + control siRNA, &p < 0.05 vs SAH + NS. TXNIP thioredoxin-interacting protein, RES resveratrol, siRNA small interfering RNA, CC3 cleaved Caspase-3, BCL-2 B cell lymphoma (BCL)-2, TUNEL terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labelling, DAPI 4′,6-diamidino-2-phenylindole